therapeutics development

AptAvian, Inc. is a biotechnology company formed in 2023 by two firms in aptamer production and airborne detection engineering to commercialize aptagenic technology platforms. It uses aptamers—single-strand DNA and RNA molecules with selective binding properties—to develop detection and therapeutic capabilities against airborne pathogens and biological threats. Over $3 million of R&D investment has produced multiple patents.

airborne pathogen detectionaptamer technologybioradar monitoringIVS (In Vivo Simulatum) testinglateral flow assay development

Astria Biosciences, Inc is a Pittsburgh-based startup company developing diagnostic and therapeutic solutions for cerebrovascular disease. It is developing a blood-based diagnostic test to detect and risk-stratify cerebral aneurysms as well as molecular-based therapies to combat this disease. Its work is supported by NSF SBIR Phase I # 2335396.

diagnosticshigh-throughput analysismolecular biology

BioIncept, a wholly owned subsidiary of Prince Biotech, is a clinical-stage biotechnology company developing breakthrough therapeutics and diagnostics built on its proprietary discovery of the PreImplantation Factor (PIF). The company is advancing novel therapies in regenerative medicine, immune modulation, and reproductive health, focused on improving IVF outcomes and tackling conditions such as autoimmunity and neuro-regeneration.

diagnostics developmentimmune modulationregenerative medicinereproductive health